InflaRx N.V. (NASDAQ:IFRX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of InflaRx N.V. (NASDAQ:IFRX) have received an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $7.50.

IFRX has been the topic of a number of analyst reports. Guggenheim increased their price objective on InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 10th. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of InflaRx in a report on Tuesday, December 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research note on Monday, December 29th. Raymond James Financial reissued an “outperform” rating on shares of InflaRx in a research note on Wednesday, December 31st. Finally, Leerink Partners restated a “market perform” rating and set a $2.00 target price (down from $5.00) on shares of InflaRx in a research report on Wednesday, December 3rd.

InflaRx Stock Performance

IFRX stock opened at $0.97 on Monday. The stock’s 50 day moving average price is $0.95 and its 200 day moving average price is $1.16. The firm has a market cap of $65.12 million, a P/E ratio of -1.43 and a beta of 1.48. InflaRx has a 1 year low of $0.71 and a 1 year high of $1.94.

Institutional Investors Weigh In On InflaRx

Several hedge funds have recently made changes to their positions in the business. Suvretta Capital Management LLC grew its position in shares of InflaRx by 22.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after purchasing an additional 1,450,000 shares during the period. 683 Capital Management LLC lifted its position in InflaRx by 47.3% during the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock worth $3,348,000 after buying an additional 1,065,000 shares during the period. Bank of America Corp DE acquired a new stake in InflaRx in the 3rd quarter worth about $3,316,000. Eversept Partners LP boosted its stake in InflaRx by 1.5% in the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock worth $1,775,000 after buying an additional 26,677 shares during the last quarter. Finally, Woodline Partners LP purchased a new stake in InflaRx in the 1st quarter valued at about $766,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.